Novo Nordisk gets obesity drug approved in Canada

The pharmaceutical company has received marketing authorization for Wegovy from Health Canada, it reports in a press release.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

The Canadian health agency, Health Canada, has approved Novo Nordisk's obesity drug Wegovy.

This was revealed in a press release on Thursday, which also stated that the company expects to launch the drug in the country in fall 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs